Consensus

EAS Consensus Position Paper Initiative

The EAS Consensus Panel, comprised of internationally renowned experts in atherosclerosis and cardiovascular disease, was first convened in November 2009 to consider the evidence for non-LDL lipids as risk factors for cardiovascular disease. To 2020 the Panel was co-chaired by Prof John Chapman (France), Prof Henry N. Ginsberg (USA), and Prof Alberico L. Catapano (Italy). 

From 2021 a new structure for the EAS Consensus Panel has been created, with coordination by Prof Alberico Catapano (Italy), Prof Lale Tokgözoğlu (Turkey) and Prof Kausik Ray (Imperial College London, UK). For each position paper topic, two or more independent chairs are appointed. These then drive the focus and content together with experts from around the world with the relevant expertise in that topic.

Taking over the role of Consensus Panel coordinators for forthcoming position papers are Prof Marianne Benn (Denmark), Prof Christoph Binder (Austria), Prof Stefano Romeo (Sweden) and Prof Jeanine Roeters van Lennep (The Netherlands).

Publications from the Consensus Position Paper Initiative

Listed in order of publication year, most recent, first.

Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society

• Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, Dumanski SM, Gulati M, Hess CN, Holven KB, Kavousi M, Kayıkçıoğlu M, Lutgens E, Michos ED, Prescott E, Stock JK, Tybjaerg-Hansen A, Wermer MJH, Benn M.
• Published August 23, 2023
• European Heart Journal, 2023. https://doi.org/10.1093/eurheartj/ehad472
• Press release: Women, lipids and atherosclerotic cardiovascular disease: A call to action from the European Atherosclerosis Society
• Lead authors comments and key messages
• Commentary: EAS issues ‘call-to-action’ statement on women, lipids, and atherosclerotic cardiovascular disease

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

• Marina Cuchel, Frederick J Raal, Robert A Hegele et al.
• Published May 3, 2023
• European Heart Journal, 2023. https://doi.org/10.1093/eurheartj/ehad197
• Press release: https://eas-society.org/2023/13700/
• Lead authors comments and key messages
• Commentary: Update to consensus statement on homozygous familial hypercholesterolaemia

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

• Florian Kronenberg, Samia Mora, Erik S.G. Stroes
• Published August 29, 2022
• European Heart Journal, 2022. https://doi.org/10.1093/eurheartj/ehac361
• Commentary: New consensus statement on lipoprotein(a)
• Lp(a) Clinical Guidance website

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease—European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement

• Jill Belch, Marianne Brodmann et al. 
• Published November 08, 2021
• Atherosclerosis, DOI: https://doi.org/10.1016/j.atherosclerosis.2021.09.022
• Commentary: Joint statement from the European Atherosclerosis Society and European Society of Vascular Medicine focuses on patients with peripheral arterial disease

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

• Henry N. Ginsberg, Chris J. Packard et al.
• Published September 02, 2021
• European Heart Journal, DOI:10.1093/eurheartj/ehab551
• Press release: New EAS Consensus on Triglyceride-rich Lipoproteins and their Remnants

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force 

• Maurizio Averna, Maciej Banach et al.
• Published: April 12, 2021
• Atherosclerosis, DOI: https://doi.org/10.1016/j.atherosclerosis.2021.03.039

Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 Agenda to fight atherosclerotic cardiovascular disease in Europe

• Paolo Parini, Lale Tokgozoglu et al.
• Published: February 16, 2021
• Atherosclerosis, DOI: https://doi.org/10.1016/j.atherosclerosis.2021.02.007
• Commentary: UN Sustainable Development Goals 2030: EAS Commitment statement

Low-density lipoproteins cause atherosclerotic cardiovascular disease; pathophysiological, genetic and therapeutic insights. A consensus statement from the European Atherosclerosis Society Consensus Panel.

• Jan Borén, M. John Chapman et al.
• Published: February 13, 2020
• European Heart Journal, DOI: https://doi.org/10.1093/eurheartj/ehz962
• Commentary “State of the art on low-density lipoproteins and cardiovascular disease”

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.

• Børge G. Nordestgaard, Michel R. Langlois et al.
• Published January 13, 2020
• Atherosclerosis DOI: https://doi.org/10.1016/j.atherosclerosis.2019.12.005
• Clin Chem Lab Med 2018 doi 10.1515/cclm-2019-1253
• Commentary “Quantifying atherogenic lipoproteins – pragmatic guidance from the EAS/EFLM Joint Consensus Initiative”
• Slides to download

Rare Dyslipidaemias: From Phenotype to Genotype to Management. A European Atherosclerosis Society Task Force Consensus Statement.

• Robert A. Hegele et al.
• Published September 30, 2019
• Lancet Diabetes Endocrinol DOI: https://doi.org/10.1016/S2213-8587(19)30264-5
• Press release “Rare lipid disorder Task Force Statement published”
• Slides to download

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

• Michel R. Langlois et al.
• Published July 01, 2018
• Clinical Chemistry DOI: https://doi.org/10.1373/clinchem.2018.287037
• Commentary “New Joint Consensus Initiative on Quantifying Atherogenic Lipoproteins”

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. A joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force.

• Francois Mach, M. John Chapman et al.
• Published April 27, 2018
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehy182
• Commentary “EAS Consensus panel answers the questions on statin safety”
• Slides to download

2017 Update of ESC/EAS Task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

• Ulf Landmesser et al.
• Published October 16, 2017
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehx549 
• Commentary “ESC/EAS Task Force issues updated clinical guidance for the use of PCSK9 inhibitors”
• Video introduction by Prof Landmesser

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. 

• Brian A. Ference et al.
• Published April 24, 2017
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehx144
• Press release
• Slides to download
• Video introduction by Prof Chapman

ESC/EAS Task Force issues updated clinical guidance for the use of PCSK9 inhibitors.

• Ulf Landmesser et al.
• Published October 27, 2016
• European Heart Journal DOI: http://doi.org/10.1093/eurheartj/ehw480 

Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the EAS and EFLM. 

• Børge G. Nordestgaard, Michel Langlois et al.
• Published April 26, 2016
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehw152
• Press release
• Slides to download
• Video introduction by Prof Nordestgaard

Familial Hypercholesterolaemia in children and adolescents: gaining decades of life by optimising detection and treatment. Consensus Statement of the European Atherosclerosis Society.

• Albert Wiegman et al.
• Published May 25, 2015
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehv157
• Commentary “Landmark Position Paper on Paediatric Familial Hypercholesterolaemia from the EAS Consensus Panel”
• Slides to download

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Consensus Statement of the European Atherosclerosis Society.

• Erik S. Stroes et al.
• Published February 18, 2015
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehv043
• Commentary “Statin–associated muscle symptoms :: Latest EAS Consensus Panel paper focuses on this neglected patient group”
• Commentary “SAMS: Statin-Associated Muscle Symptoms – Update 2017”
• Slides to download

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. Consensus Statement of the European Atherosclerosis Society. 

• Marina Cuchel et al.
• Published August 24, 2014
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehu274
• Commentary “Consensus on Homozygous FH”
• Slides to download

Consensus Position Paper on plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Consensus Statement of the European Atherosclerosis Society. 

• Helena Gylling et al.
• Published February 01, 2014
• Atherosclerosis DOI: http://doi.org/10.1016/j.atherosclerosis.2013.11.043
• Commentary “Focus on lifestyle: EAS Consensus Panel Position Statement on phytosterol-added foods”

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Consensus Statement of the European Atherosclerosis Society.

• Robert Hegele et al.
• Published December 23, 2013
• Lancet Diabetes Endocrinol DOI: https://doi.org/10.1016/S2213-8587(13)70191-8
• Commentary “Simplifying the definition of hypertriglyceridaemia”

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. 

• Børge G. Nordestgaard, M. John Chapman et al.
• Published August 15, 2013
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/eht273
• Slides to download
• Commentary “EAS Consensus Statement on FH: Improving the care of FH patients“

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Consensus Statement of the European Atherosclerosis Society.

• M. John Chapman, Henry N. Ginsberg et al.
• Published April 29, 2011
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehr112
• Slides to download

Lipoprotein(a) as a cardiovascular risk factor: current status. Consensus Statement of the European Atherosclerosis Society.

• Børge G. Nordestgaard, M. John Chapman et al.
• Published October 21, 2010
• European Heart Journal DOI: https://doi.org/10.1093/eurheartj/ehq386
• Slides to download